ReviewGut2018
Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.
Open access · bronzeAbstract readReview
In one paragraph
Review in Gut, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 1 synthesis or guideline pooled it, 166 citations in OpenAlex.
- The role of lipid metabolic reprogramming in tumor microenvironment.Theranostics · 2023Pooled it
- Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance).International journal of cancer · 2019Trial
- Beyond tumor biology: nursing interventions for psychological and immune health in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Life's Essential 8 and the Risk of Overall and Specific-Site Cancer Types: A Large-Scale Prospective Cohort Study.Cancer medicine · 2026Article
- The Interplay of Autoimmune Disease, Cancer, and Immunity: Current Understanding and Therapeutic Prospects.International journal of hematology-oncology and stem cell research · 2025Review
- A Novel Ensemble Framework for Comprehensive Early-Stage Colorectal Cancer Diagnosis, Prognosis, and Treatment: Integration of Gastroenterology-Specific Transformer Language Models and Multiple Decision Trees.Journal of clinical medicine · 2025Article
- Predicting Prognosis and Immunotherapy Response in Glioblastoma (GBM) With a 5-Gene CAF-Risk Signature.Cancer reports (Hoboken, N.J.) · 2025Article
- Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications.Immunity, inflammation and disease · 2025Review
- Deciphering the integrated immunogenomic landscape of colorectal cancer: insights from Mendelian randomization and immune-stratified molecular subtyping.BMC gastroenterology · 2025Article
- Review
- Integrated multi-omics unveils novel immune signature for predicting prognosis in colon cancer patients.Scientific reports · 2025Article
- Editorial: Community series in: the role of vitamin D as an immunomodulator, volume II.Frontiers in immunology · 2025Article
- A mitochondrial lipid metabolism-related gene signature predicts prognosis and immune landscape in colorectal cancer.Frontiers in immunology · 2025Article
- Review
- MALDI imaging combined with two-photon microscopy reveals local differences in the heterogeneity of colorectal cancer.Npj imaging · 2024Article
- Mitochondrial function and gastrointestinal diseases.Nature reviews. Gastroenterology & hepatology · 2024Review
- Targeting the lipid metabolic reprogramming of tumor-associated macrophages: A novel insight into cancer immunotherapy.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- The microbiome and rise of early-onset cancers: knowledge gaps and research opportunities.Gut microbes · 2023Review
- Heterogeneity of the tumor immune microenvironment and clinical interventions.Frontiers of medicine · 2023Review
- Macrophage's role in solid tumors: two edges of a sword.Cancer cell international · 2023Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Shuji OginoProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jonathan A NowakProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Tsuyoshi HamadaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Amanda I PhippsPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Ulrike PetersPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Danny A MilnerAmerican Society for Clinical Pathology, Chicago, Illinois, USA.
Edward L GiovannucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Reiko NishiharaProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Marios GiannakisBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA.
Wendy S GarrettBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA.
Mingyang SongDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USHarvard University · USAmerican Society for Clinical Pathology · USFred Hutch Cancer Center · USMassachusetts General Hospital · USMassachusetts Institute of Technology · USUniversity of Washington · US
Funding
Molecular pathological epidemiology of colorectal cancerU01CA137088 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERS, ULRIKE · 2009 to 2018
$21.8MHarvard Clinical and Translational Science CenterKL2TR001100 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$8.5MAccelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0MGut microbiota and inflammatory monocytes in colorectal cancerR01CA154426 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI GARRETT, WENDY S. · 2011 to 2025
$5.2MMarine Omega-3 Polyunsaturated Fatty Acid, Gut Microbiome, and Colorectal Cancer PreventionR00CA215314 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI SONG, MINGYANG · 2018 to 2020
$679kLifestyle, genetics and colonoscopy for colorectal cancer preventionK07CA190673 · NCI · DANA-FARBER CANCER INST · PI NISHIHARA, REIKO · 2014 to 2018
$609kLifestyle Factors and Survival Outcomes for Colorectal Cancer Molecular SubtypesK07CA172298 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PHIPPS, AMANDA IRENE · 2013 to 2016
$406kNCATS NIH HHS KL2 TR001100NCI NIH HHS K07 CA172298NCI NIH HHS K07 CA190673NCI NIH HHS R00 CA215314NCI NIH HHS R01 CA154426NCI NIH HHS R35 CA197735NCI NIH HHS U01 CA137088
Abstract
Immunotherapy strategies targeting immune checkpoints such as the
Indexed as
Precision MedicineAllergy and ImmunologyHumansImmunologic FactorsImmunotherapyNeoplasmsPathology, MolecularImmunologic Factorscancer epidemiologycancer Immunobiologycancer preventioncolorectal carcinomamolecular pathology
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.